Homepage > Company > Media > Pharma News > 2016 > Teva Launches Generic Campral In U.S.

Teva Launches Generic Campral In U.S.

Teva Pharmaceutical Industries Ltd., (TEVA) said it has launched the generic equivalent to Campral, or acamprosate calcium, delayed-release tablets, 333 mg, in the U.S.

Acamprosate calcium delayed-release tablets are used for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at the start of treatment.

Treatment with acamprosate calcium delayed-release tablets helps maintain abstinence from alcohol only when used as part of a treatment program that includes counseling and support.

Acamprosate calcium delayed-release tablets had annual sales of about $14 million in the U.S., according to IMS data as of December 2015. With over 375 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market.

by RTT Staff Writer

3/22/2016

Source:

Read also

NICE Recommends Sanofi and Regeneron’s Libtayo for CSCC

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Sanofi and Regeneron’s Libtayo (cemiplimab) for National Health Service (NHS) use in the treatment of patients ...

United Therapeutics’ Tyvaso DPI Approved for Rare High Blood Pressure Disease

The FDA has approved United Therapeutics’ Tyvaso DPI (trepostinil) in an inhaled powder formulation for patients with pulmonary arterial hypertension, a rare type of high blood pressure dis...

UCLA Researchers Identify HIV Drug That Could Combat Memory Loss

Researchers at the University of California, Los Angeles have identified a neurological mechanism behind memory linking.

Senate Passes Legislation to Address Medication Accessibility, Affordability

Senate Majority to Advance Legislation to Make Prescription Drugs More Affordable.